Skip to main content

Closed

NAMS: NewAmsterdam Pharma Company N.V. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Operating margin-953.6%

ROIC-32.3%

Financially safe

Stretched

Debt / equity0.00×

Interest coverage0.0×

Current ratio9.76×

NewAmsterdam Pharma Company N.V.

NAMSNASDAQ·USD·Closed

NewAmsterdam Pharma Company N.V.

NAMSNASDAQ·USD·Closed

$27.79

−2.35%

$27.79

−$0.67 (2.35%)

52W Range

32thpctl

Volume

0.73×avg

Mkt Cap

3.25BUSD

P/E

-15.4TTM

Div Yield

–ann

52W Range

32thpctl

Volume

0.73×avg

Market Cap

3.25BUSD

P/E Ratio

-15.4TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings